FDA Label for One Touch Advanced Topical Anesthetic Bubble Gum

View Indications, Usage & Precautions

One Touch Advanced Topical Anesthetic Bubble Gum Product Label

The following document was submitted to the FDA by the labeler of this product Hager Worldwide, Inc.. The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information. Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive ingredients, etc.

Description



OneTouch
Advanced

Topical Anesthetic Gel                                                                                                                                                                           Rx
Only
Active Ingredients:
Benzocaine
14.0%
Butamben
2.0%
Tetracaine Hydrochloride
2.0%

Inactive Ingredient



Inactive Ingredients:
Benzalkonium chloride
0.5%
Cetyl Dimethyl Ethyl Ammonium Bromide
0.005%
In bland, water-soluble base.


Mechanism Of Action



ActionThe onset of OneTouch Advanced-produced anesthesia is rapid (approximately30 seconds) and the duration of anesthesia is typically 30-60 minutes, whenused as directed. This effect is due to the rapid onset, but short duration ofaction of Benzocaine coupled with the slow onset, but extended duration ofTetracaine HCI and bridged by the intermediate action of Butamben.It is believed that all of these agents act by reversibly blocking nerve conduc-­tion. Speed and duration of action is determined by the ability of the agent tobe absorbed by the mucous membrane and nerve sheath and then to diffuseout, and ultimately be metabolized (primarily by plasma cholinesterases) to inertmetabolites which are excreted in the urine.

Indications & Usage



Indications
OneTouch Advanced Gel is a topical anesthetic indicated for the production
of anesthesia of all accessible mucous membrane except the eyes. OneTouch
Advanced Gel is indicated for use to control pain in the mouth.


Dosage & Administration



Dosage and Administration
Only a limited quantity is OneTouch Advanced Gel is required for anesthesia.

Dispense 200 mg of gel (a bead approximately 1/4 to 1/2 inches long) by gently
depressing the pump.  Dispensing a bead of gel in excess of 400 mg is contrain-­
dicated. Spread thinly and evenly over the desired area using a cotton swab.

An appropriate pediatric dosage has not been established for OneTouch Ad-­
vanced Gel.

Dosages should be reduced in the debilitated elderly, acutely ill, and very young
patients.

Tissue need not be dried prior to application of OneTouch Advanced Gel. One-
Touch Advanced Gel should be applied directly to the site where pain control is
required. Anesthesia is produced within one minute with an approximate duration
of thirty minutes. Each 200 mg dose of OneTouch Advanced Gel contains 28 mg
of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCI.


Adverse Reactions



Adverse Reactions Hypersensitivity Reactions: Unpredictable adverse reactions (i.e. hypersensi-­tivity, including anaphylaxis) are extremely rare.Localized allergic reactions may occur after prolonged or repeated use of anyaminobenzoate anesthetic. The most common adverse reaction caused bylocal anesthetics is contact dermatitis characterized by erythema and pruritusthat may progress to vesiculation and oozing. This occurs most commonly inpatients following prolonged self-medication, which is contraindicated. If rash,urticaria, edema, or other manifestations of allergy develop during use, the drugshould be discontinued. To minimize the possibility of a serious allergic reaction,OneTouch Advanced Gel should not be applied for prolonged periods exceptunder continual supervision. Dehydration of the epithelium or an escharotic ef-­fect may also result from prolonged contact.

Precautions



Precaution: On rare occasions, methemoglobinemia has been reported in
connection with the use of benzocaine-containing products. Care should be
used not to exceed the maximum recommended dosage (see Dosage and
Administration). If a patient becomes cyanotic, treat appropriately to counteract
(such as with methylene blue, if medically indicated).


Pregnancy



Use in Pregnancy: Safe use of One Touch Advanced Gel has not beenestablished with respect to possible adverse effects upon fetal development.Therefore, OneTouch Advanced Gel should not be used during early pregnancy,unless in the judgement of a physician, the potential benefits outweigh the un-­known hazards. Routine precaution for the use of any topical anesthetic shouldbe observed when OneTouch Advanced Gel is used.

Contraindications



Contraindications
OneTouch Advanced Gel is not suitable and should never be used for injection.
Do not use on the eyes. To avoid excessive systemic absorption, OneTouch
Advanced Gel should not be applied to large areas of denuded or inflamed
tissue. OneTouch Advanced Gel should not be administered to patients who are
hypersensitive to any of its ingredients or to patients known to have cholinest-­
erase deficiencies. Tolerance may vary with status of the patient.
 
OneTouch Advanced Gel should not be used under dentures or cotton rolls, as
retention of the active gel ingredients under a denture or cotton roll could pos-­
sibly cause an escharotic effect. Routine precaution for the use of any topical
anesthetic should be observed when using OneTouch Advanced Gel.


How Supplied



How-Supplied
OneTouch Advanced Gel, 32 g jar

Cool Mint
NDC 62565-901-01
Strawberry Ice
NDC 62565-902-01
Bubble Gum
NDC 62565-903-01
Cherry
NDC 62565-904-01
Manufactured for
HAGER
WORLDWIDE

13322 Byrd Drive
Odessa, FL 33556 USA

Made in U.S.A.        Rev. 6/09


Package Label.Principal Display Panel



Caution: Rx Only.
Do not use in eyes.  Keep out of reach of children.

Directions: Read package insert.
Press top of container to dispense desired amount.
Dispense 200 mg of gel (a bead approximately
1/4 to 1/2 inches long) by gently depressing the
pump.  Dispensing a bead in excess of 400 mg is
contraindicated.  Spread thinly and evenly over the
desired area using a cotton swab.

Active Ingredients: Benzocaine 14.0%,
Butamben 2.0%, Tetracaine Hydrochloride 2.0%
Inactive Ingredients: Benzalkonium Chloride
0.5%, Cetyl Dimethyl Ethyl Ammonium Bromide
0.005%, in a bland water-soluble base.
NDC 62565-903-01
OneTouch
Advanced


Topical Anesthetic Gel

OneTouch Advanced
is indicated for anesthesia of
accessible mucous membrane.


Bubble Gum
Net Wt. 32 g


Store in a cool dry place.





Manufactured for:
HAGER
WORLDWIDE
Odessa, FL  33556 USA


Item #6256590301



Made in U.S.A.   Rev. 05/09

* Please review the disclaimer below.